Tonix Pharmaceuticals Holding Corp (NASDAQ:
TNXP) is
one of the top long-term biotechnology stocks to buy. On October 17, Tonix Pharmaceuticals (NASDAQ:TNXP) presented encouraging preclinical data for its investigational mpox and smallpox vaccine candidate, TNX-801, at the World Vaccine Congress Europe 2025.
The live, attenuated horsepox-based vaccine elicited strong immune responses, provided long-term protection, and demonstrated favorable safety across multiple animal models. A single dose provided durable immunity for at least 14 months and was well-tolerated across various delivery methods. Despite promising results, Tonix remains unprofitable, and analysts do not expect profitability this year.
TNX-801 is designed to be minimally replicative and may offer advantages over existing vaccines. The company has also engaged the FDA and partnered with the Kenya Medical Research Institute to pursue a Phase I clinical trial. It is also exploring microneedle patch technology to simplify future vaccine administration.
Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) is a biopharmaceutical company that develops and commercializes therapies and vaccines for various diseases. Its work focuses on four main areas: central nervous system disorders, immunology, infectious diseases, and rare diseases. The company also markets existing products, such as Zembrace SymTouch and Tosymra, for the treatment of acute migraine headaches.
While we acknowledge the potential of TNXP as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the
best short-term AI stock.
READ NEXT: Billionaire Steve Cohen’s 10 Small-Cap Stock Picks with Huge Upside Potential and
Top 9 Credit Services Stocks to Buy as the US Cuts Interest Rates.
Disclosure: None. This article is originally published at
Insider Monkey.
